Stay updated with breaking news from Christopher Causey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leerink Partnrs reissued their outperform rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2023 earnings at $4.28 EPS, FY2023 earnings at $19.79 EPS, Q1 2024 earnings at $5.07 EPS, Q2 2024 earnings at $5.25 EPS, Q3 […]
Weil Company Inc. lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 0.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 48,020 shares of the biotechnology company’s stock after selling 246 shares during the quarter. United Therapeutics comprises 5.4% of Weil […]
L2 Asset Management LLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 95.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 579 shares of the biotechnology company’s stock after selling 11,438 shares during the […]
Assenagon Asset Management S.A. reduced its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 81.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,133 shares of the biotechnology company’s stock after selling 399,050 shares during the quarter. Assenagon Asset Management […]
LSV Asset Management raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 1.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 383,068 shares of the biotechnology company’s stock after acquiring an additional 3,700 shares during the […]